Difference between revisions of "HFSA/ACC/AHA, et al, (Accessed April 1, 2020), cited as Ref 23 in DOI: 10.1007/s11886-020-01293-2 (Q11017)"
Jump to navigation
Jump to search
(Added link to [sliswiki]: HFSA/ACC/AHA, et al, (Accessed April 1, 2020), cited as Ref 23 in DOI: 10.1007/s11886-020-01293-2, #quickstatements; #temporary_batch_1592834880701) |
(Created claim: title (P93): HFSA/ACC/AHA Joint Statement addressing concerns re: using RAAS antagonists in COVID-19., #quickstatements; #temporary_batch_1592835264664) |
||
| Property / title | |||
| + | HFSA/ACC/AHA Joint Statement addressing concerns re: using RAAS antagonists in COVID-19. (English) | ||
| Property / title: HFSA/ACC/AHA Joint Statement addressing concerns re: using RAAS antagonists in COVID-19. (English) / rank | |||
| + | Normal rank | ||
Revision as of 14:16, 22 June 2020
Cited in: "Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty" Curr Cardiol Rep; 2020 04 29 ; 22 (5) 34.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
HFSA/ACC/AHA, et al, (Accessed April 1, 2020), cited as Ref 23 in DOI: 10.1007/s11886-020-01293-2
|
Cited in: "Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty" Curr Cardiol Rep; 2020 04 29 ; 22 (5) 34.
|
Statements
HFSA/ACC/AHA Joint Statement addressing concerns re: using RAAS antagonists in COVID-19. (English)
0 references
